ISIan Sayers

Ian Sayers

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ian Sayers has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Topology-Based Query Framework for Longitudinal Omics Trajectories

    by Nazanin Zounemat-Kermani, Matthew Richardson, Alen Faiz, Siyao Wang, Kai Sun, Dragana Vuckovic, Maarten van Den Berge, Anke-Hilse Maitland-Van der Zee, Ian Sayers, Sven-Erik Dahlén, et al.

    1 1.1 Background: Many longitudinal omics studies contain only a small number of repeated measurements collected before, during, or after an intervention. Existing approaches, including mixed-effects models and generalized additive models, estimate temporal effects but do not generally provide a discrete representation of trajectory topology that can be queried directly across experimental groups. 1.2 Methods: We developed LongOmicsTraj, an open-source R package for topology-based representation and querying of short longitudinal omics trajectories. The framework encodes the direction of change between adjacent visits as up , down , or flat , with the ordered sequence defining an Ordinal Trajectory State (OTS). LongOmicsTraj operates downstream of trajectory estimation and can therefore be applied to empirical summaries or model-derived visit-level estimates, including those from linear mixed-effects models, generalized additive models, and polynomial regression, following a maSigPro-style time-course formulation [1]. OTS labels provide a common representation for topology-based querying, cross-group comparison, and evaluation of higher-level representations such as trajectory clusters. We evaluated the framework using controlled simulations and bronchial biopsy transcriptomic data from the GLUCOLD corticosteroid intervention study (GEO accession GSE36221 ), measured at baseline, 6 months, and 30 months. The biological analysis compared continued inhaled corticosteroid (ICS) treatment, ICS withdrawal after 6 months, and placebo. 1.3 Results: In simulations, LongOmicsTraj recovered predefined stable, monotonic, transient, rebound, and oscillatory trajectories with high accuracy when longitudinal signal was sufficiently clear, with performance declining under high-noise conditions and depending partly on the upstream estimator. In GLUCOLD, comparator-aware topology queries reduced 20,358 measured transcripts to 168 genes showing a corticosteroid response that was maintained during continued treatment, reversed following withdrawal, and was not reproduced under placebo. The selected genes included established corticosteroid-response genes and were enriched for immune-cell migration, chemotaxis, cell adhesion, and extracellular-matrix organisation. Topology-aware evaluation of FlexMix trajectory clusters additionally revealed substantial within-cluster temporal heterogeneity, with topology purities of approximately 46–60%. 1.4 Conclusions: LongOmicsTraj provides a compact, directly queryable representation of temporal direction and order in short longitudinal omics studies. It complements existing longitudinal estimation and clustering methods by making trajectory structure explicit, enabling structured cross-group queries and quantification of temporal heterogeneity within trajectory clusters.

  • Open Access

    Clinical parameters and blood biomarkers associated with response to mepolizumab in severe asthma

    by Yik Pang, James Eastall, Alexander Clay, Robert J. Hall, Mohammad R. Ali, Dominick Shaw, Ian Sayers

    Background: Mepolizumab is effective for a subset of severe asthma patients in reducing exacerbation frequency. Identification of an early marker associated with long-term beneficial clinical response would facilitate better targeting of treatment. We set out to determine the impact of mepolizumab from a clinical, blood inflammatory cell and serum proteomics perspective and identify early changes in patients designated responder/non-responder at one year. Methods: We enrolled asthma patients that met criteria to be prescribed mepolizumab. Patients had clinical and blood cell measurements at baseline, 12 and 26 weeks. Serum proteomics (Alamar NULISA, 250 panel) was completed at baseline and 12 weeks. Results: 37 patients completed the study (24 and 13 responder and non-responder respectively at 1 year). Both Asthma Control Questionnaire (ACQ)-6 and Severe Asthma Questionnaire (SAQ) improved at 12 and 26 weeks and were driven by the responder group. A reduction in blood eosinophils and basophils was observed. There was a significant elevation of only 2/248 serum proteins, IL5 and CCL24 after 12 weeks mepolizumab treatment, with elevation being driven by the responder and non-responder groups respectively. A 12-week improvement in SAQ was associated with higher odds of response at one year (OR 6.75, 95% CI 1.42–24.30; p=0.015). Conclusions: We identified early changes in the clinical and protein profile in patients that go onto have a clinically relevant response to mepolizumab providing opportunities for a more personalised asthma management.

  • Open Access

    Lung function candidate genes in Drosophila melanogaster

    by Emma Szamek, Zsuzsa Markus, Marina Molina Altamirano, Núria Corbella-Rius, Ian Adcock, Sofia J. Araújo, Ian Sayers, Marios Georgiou

    Rationale: Chronic obstructive pulmonary disease (COPD) represents a leading cause of global morbidity and mortality. Genome-wide association studies (GWAS) have implicated numerous genetic variants in lung function impairment, yet confidently identifying the underlying genes and pathways, and translating these findings into mechanistic insight, remains a significant challenge. Objectives: To leverage the genetic amenability and high-throughput screening capability of Drosophila melanogaster to determine the role of candidate causal genes in epithelial cell homeostasis. Methods: We performed a loss-of-function analysis of 60 prioritised lung function candidate causal genes implicated from GWAS in two distinct epithelia: the dorsal thorax and trachea. Results: We identified 57/60 tested candidate genes that alter at least one aspect of epithelial morphology and behaviour upon knockdown. With a focus on junctional integrity, cell delamination and tissue growth, we identified 11 genes for further study: Sec6, RpS26, pAbp, Arf102f, Riok1, Sra-1, Inpp5e, CG31759, ssh, eIF6 and Rtf1 . Further characterisation found a significant reduction in junctional E-Cadherin levels following Arf102F , Rtf1 , RioK1 and Sra-1 knockdown. Following a secondary screen in the Drosophila tracheal system for priority candidates, Sec6 and RpS26 were associated with significant airway defects and a reduction in larval body size. 8/11 priority genes exhibited differential lung gene expression between controls and patients with COPD. Conclusions: These data demonstrate the amenability of Drosophila melanogaster to perform in vivo functional analyses of candidate causal genes at scale. Initial findings implicate several genes in epithelial homeostasis and integrity, providing new mechanistic understanding and potential therapeutic targets for COPD. Graphical

  • Open Access

    Genome-wide association study of idiopathic pulmonary fibrosis susceptibility using clinically curated European ancestry datasets

    by Daniel Chin, Tamara Hernandez-Beeftink, Lauren Donoghue, Beatriz Guillen-Guio, Olivia C. Leavy, Ayodeji Adegunsoye, Helen L. Booth, CleanUP-IPF Investigators of the Pulmonary Trials Cooperative, William A. Fahy, Tasha E. Fingerlin, et al.

    Extract Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease thought to result from an aberrant response to lung injury, culminating in an exaggerated healing response with excessive deposition of extracellular matrix in the interstitium [1].


  • Open Access

    Genome-wide association study of asthma with high treatment burden and/or worse outcomes defined using electronic healthcare data in UK Biobank

    by Noemi N. Piga, Michael A. Portelli, Nick Shrine, Jing Chen, Richard Packer, Kayesha Coley, Alexander T. Williams, Chiara Batini, Catherine John, Sharon M. Lutz, et al.

    Background: In approximately 10% of asthma patients, symptoms remain uncontrolled despite maximal treatment, representing an unmet clinical need. The causal variants, genes and pathways underlying genetic risk factors have not been fully elucidated, and it is unclear whether there are unique genetic risk factors for this asthma subtype. Methods: We used electronic healthcare records (EHR) linked to UK Biobank to identify asthma patients with high treatment burden and/or worse outcomes. We performed a genome-wide association study (GWAS) with this case population and healthy controls. We sought replication for associated (p≤5×10 −6 ) signals in four independent studies (12 152 cases and 32 316 controls). Replicated signals were fine-mapped and linked to genes and pathways. Results: In total, 7681 participants met our case definition and showed enrichment for adult-onset asthma, female gender and higher BMI compared to asthma individuals not meeting case criteria. GWAS with 7681 cases and 38 405 controls revealed 21 reproducible association signals that had previously been associated with asthma but had a larger effect size in our study. Variant-to-gene mapping highlighted 85 candidate genes, five of which were considered high confidence ( BACH2 , D2HGDH , IL1RL1 , RPS26 , SMAD3 ). Conclusion: We present the first use of EHR in UK Biobank to identify a subtype of asthma enriched for patients with high treatment burden and/or worse outcomes. Our findings support the role of known asthma genes, highlighting genetic risk variants with stronger effect in these groups of patients. The prioritised genes provide potential therapeutic opportunities for this difficult-to-treat patient population.

  • Open Access

    Sex-specific genetic effects on susceptibility to idiopathic pulmonary fibrosis

    by Olivia C Leavy, Anne F Goemans, Tamara Hernandez-Beeftink, Amy D Stockwell, Richard J Allen, Beatriz Guillen-Guio, Ayodeji Adegunsoye, Helen L Booth, William A Fahy, Tasha E Fingerlin, et al.

    Background: Idiopathic pulmonary fibrosis (IPF) is a chronic lung condition that is more prevalent in males than females. The reasons for this are not fully understood, with differing environmental exposures due to historically sex-biased occupations, or diagnostic bias, being possible explanations. To date, over 20 independent genetic association signals have been reported for IPF susceptibility, but these have been discovered when combining males and females.Objectives: To assess whether there is a need to consider sex-specific effects when evaluating genetic risk in clinical prediction models for IPF and to test for sex-specific associations with IPF susceptibility.Methods: We performed a genome-wide single nucleotide polymorphism (SNP)-by-sex interaction study meta-analysis of IPF risk in six independent case-control studies. comprising 4561 cases (1280 females, 2281 males) and 23 500 controls (8360 females, 14 528 males) of European genetic ancestry. We used polygenic risk scores (PRS) comprising common (minor allele frequency>1%) autosomal variants to assess differences in genetic risk prediction between males and females.Results: The predictive accuracy of the PRSs were similar between males and females, regardless of whether using combined or sex-specific association results. Three new independent genetic association signals were identified (p−6).Conclusions: The predictive accuracy of common autosomal SNP-based PRSs did not vary significantly between males and females. We prioritised three genetic variants whose effect on IPF risk may be modified by sex. These findings would not account for the differences in prevalence between males and females. Future studies should ensure adequate representation of both sexes.


  • Open Access

    Epithelial Interleukin‐1 Receptor‐Like‐1 Activation Is Contingent on Interleukin‐33 Isoforms and Asthma‐Related Receptor Variation

    by Michael A. Portelli, Maria E. Ketelaar, Stewart Bates, Eszter Csomor, Dominick Shaw, Jonas Emsley, Christopher Brightling, Ian Hall, Karen Affleck, Matthew Edwards, et al.

    Introduction: The interleukin‐33/interleukin‐1 receptor‐like‐1 (IL‐33/IL1RL1) signalling pathway is implicated in asthma pathogenesis, with IL1RL1 nonsynonymous genetic polymorphisms associated with disease risk. We aimed to determine these variants' effect on IL1RL1 signalling induced by different IL33 isoforms thought to be elevated in the asthmatic airway.Method: In a project funded by GSK plc, which has developed an IL‐33 receptor inhibitor for asthma treatment, human embryonic kidney 293 (HEK293) cells expressing secreted embryonic alkaline phosphatase (SEAP) driven by a nuclear factor kappa‐beta (NF‐κB) promoter, were transiently transfected with IL1RL1, containing one of four extracellular and Toll/interleukin 1 receptor (TIR) domain haplotypes. Cells were stimulated with seven different splice and proteolytic‐generated IL‐33 isoforms (0.001–50 ng/mL) for 24 h. Supernatant SEAP activity and interleukin‐8 (IL‐8) levels were determined. Primary human bronchial epithelial cells (HBECs) representing different genotype carriers were stimulated with IL‐33112–270 (50 ng/mL) and induced IL‐8 mRNA expression measured.Results: HEK293 cells carrying both asthma extracellular and TIR domain IL1RL1 risk haplotypes presented maximal IL33‐driven signalling, with minimal signalling after IL‐33 activation in other protective haplotypes. All IL‐33 isoforms activated IL1RL1 but with differing magnitudes. Proteolytically cleaved IL3395–270 and IL33106–270 had the greatest effect and the IL33113–270, and Exon 3,4 deletion isoform exhibited the lowest. The effect of extracellular and TIR domain genetic variants on receptor signalling was replicated in primary HBECs. Maximal IL1RL1 signalling was observed in cells carrying both extracellular and TIR signalling domain risk haplotypes.Conclusions: Overall, our study suggests asthma patients carrying the extracellular and TIR domain risk haplotype and have a lung microenvironment that promotes elevated levels of cleaved IL33, particularly where IL3395–270 and IL33106–270 may be more amenable to IL33/IL1RL1 targeting.


  • Open Access

    Defining an Ageing-Related Pathology, Disease or Syndrome: International Consensus Statement

    by Emma Short, Ian M. Adcock, Bilal Al-Sarireh, Ann Ager, Ramzi Ajjan, Naveed Akbar, Michael A. Akeroyd, Ghada Alsaleh, Ghada Al-Sharbatee, Kambiz Alavian, et al.

    Background: Around the world, individuals are living longer, but an increased average lifespan does not always equate to an increased healthspan. With advancing age, the increased prevalence of ageing-related diseases can have a significant impact on health status, functional capacity, and quality of life. It is therefore vital to develop comprehensive classification and staging systems for ageing-related pathologies, diseases and syndromes. This will allow societies to better identify, quantify, understand, and meet the healthcare, workforce, wellbeing, and socioeconomic needs of ageing populations, while supporting the development and utilisation of interventions to prevent or to slow, halt or reverse the progression of ageing-related pathologies. Methods: The foundation for developing such classification and staging systems is to define the scope of what constitutes an ageing-related pathology, disease or syndrome. To this end, a consensus meeting was hosted by the International Consortium to Classify Ageing-Related Pathologies (ICCARP), on February 19 th , 2024, in Cardiff, UK, and was attended by 150 recognised experts. Discussions and voting were centred on provisional criteria that had been distributed prior to the meeting. The participants debated and voted on these. Each criterion required a consensus agreement of ≥70% for approval. Results: The accepted criteria for an ageing-related pathology, disease or syndrome were: Develops and/or progresses with increasing chronological age. Should be associated with, or contribute to, functional decline, or an increased susceptibility to functional decline. Evidenced by studies in humans. Conclusions: Criteria for an ageing-related pathology, disease or syndrome have been agreed by an international consortium of subject experts. These criteria will now be used by the ICCARP for the classification and ultimately staging of ageing-related pathologies, diseases and syndromes.


  • Open Access

    IL-33 induced gene expression in activated Th2 effector cells is dependent on IL-1RL1 haplotype and asthma status

    by Akshaya Keerthi Saikumar Jayalatha, Marlies E. Ketelaar, Laura Hesse, Yusef E. Badi, Nazanin Zounemat-Kermani, Sharon Brouwer, Nicole F. Dijk, Maarten van Den Berge, Victor Guryev, Ian Sayers, et al.

    Asthma is a heterogeneous respiratory disease caused by the interaction between environmental and genetic factors [1]. The IL-33 and IL-1RL1 genes are strongly associated with childhood-onset and type-2 high asthma, and the asthma risk alleles amplify interleukin (IL)-33 pathway activity [2]. Environmental factors, such as allergens and viral infections, trigger bronchial epithelial cells to release IL-33, which can activate signalling by binding to the IL-1RL1/IL-1RAcP receptor complex [3], and contribute to hyper-responsiveness, remodelling and chronic type 2 inflammation of the airways [4].


  • Mepolizumab-induced Changes in Nasal Methylome and Transcriptome to Predict Response in Asthma

    by Kamini Rakkar, Yik L. Pang, Poojitha Rajasekar, Michael A. Portelli, Robert J. Hall, Rachel L. Clifford, Dominick Shaw, Ian Sayers